标题:阿托伐他汀联合贝那普利治疗 IgA肾病的疗效及对患者尿蛋白、血肌酐水平的影响
作者:赵洁 1,蒙军平 1,王薇 1,周璐 1,刘佩 2 1.空军军医大学唐都医院肾脏内科,陕西 西安 710038;2.西安高新医院肾脏内科,陕西 西安 710075
卷次:
2019年30卷22期
【摘要】 目的 观察阿托伐他汀联合贝那普利治疗 IgA肾病患者的疗效,并探讨其对患者尿蛋白、血肌酐(Scr)水平的影响。方法 回顾性分析2014年1月至2017年12月在空军军医大学唐都医院肾脏内科治疗的66例 IgA肾病患者的临床资料,根据治疗方法的不同分为对照组和联合治疗组各33例,对照组采用贝那普利治疗,联合治疗组采用阿托伐他汀联合贝那普利治疗,疗程均为3个月。两组患者均于疗程结束后评估治疗疗效,比较两组患者治疗前、治疗1个月、2个月、3个月后的24 h尿蛋白定量和Scr水平。结果 联合治疗组患者的治疗总有效率为90.91%,明显高于对照组的66.67%,差异有统计学意义(P<0.05);两组患者治疗前24 h尿蛋白定量水平比较差异无统计学意义(P>0.05);两组患者治疗后24 h尿蛋白定量水平均较治疗前明显降低,治疗1个月、2个月、3个月后,联合治疗组患者的 24 h尿蛋白定量水平分别为(0.85±0.76) g、(0.70±0.63) g、(0.60±0.55) g,明显低于对照组的(1.73±0.79) g、(1.61±0.82) g、(1.34±0.76) g,差异均有统计学意义(P<0.05);两组患者治疗前的Scr水平比较差异无统计学意义(P>0.05);两组患者治疗后Scr水平均较治疗前明显降低,治疗1个月、2个月、3个月后,联合治疗组患者的Scr水平分别为(131.90±12.69) mmol/L、(114.73±8.59) mmol/L、(105.65±5.51) mmol/L,明显低于对照组的(146.59±13.74) mmol/L、(135.66±12.88) mmol/L、(128.34±10.79) mmol/L,差异均有统计学意义(P<0.05)。结论 阿托伐他汀联合贝那普利治疗 IgA肾病可有效降低患者的24 h尿蛋白定量和Scr水平,提高患者的治疗效果。
【关键词】 阿托伐他汀;贝那普利;IgA肾病;疗效;尿蛋白;血肌酐
【中图分类号】 R692 【文献标识码】 A 【文章编号】 1003—6350(2019)22—2876—03
Efficacy of atorvastatin combined with benazepril in the treatment of IgA nephropathy and its effect on urineprotein and serum creatinine levels.
ZHAO Jie 1, MENG Jun-ping 1, WANG Wei 1, ZHOU Lu 1, LIU Pei 2. 1. Department ofNephrology, Tangdu Hospital of Air Force Military Medical University, Xi'an 710038, Shaanxi, CHINA; 2. Department ofNephrology, Xi'an High-tech Hospital, Xi'an 710075, Shaanxi, CHINA
【Abstract】 Objective To observe the efficacy of atorvastatin combined with benazepril in the treatment of IgAnephropathy, and to explore its effect on urine protein and serum creatinine (Scr) levels. Methods The clinical data of66 patients with IgA nephropathy treated by Department of Nephrology, Tangdu Hospital of Air Force Military MedicalUniversity from January 2014 to December 2017 were retrospectively analyzed. According to the different treatmentmethods, the patients were divided into the control group (n=33) and combined treatment group (n=33). The controlgroup was treated with benazepril, and the combined treatment group was treated with atorvastatin plus benazepril for 3months. Both groups of patients were evaluated for therapeutic efficacy at the end of the treatment period. The 24-hoururine protein quantitation and Scr levels were compared between the two groups before treatment, 1 month, 2 months,and 3 months after treatment. Results The total effective rate of the combined treatment group was 90.91%, which wassignificantly higher than 66.67% of the control group (P<0.05). There was no significant difference in the urine proteinlevel between the two groups before treatment (P>0.05). The urinary protein quantification level of the two groups wassignificantly lower than that before treatment. The 24-hour urine protein quantitation levels of the patients in the combinedtreatment group after 1 month, 2 months and 3 months of treatment were (0.85±0.76) g, (0.70±0.63) g, (0.60±0.55) g,which was significantly lower than (1.73±0.79) g, (1.61±0.82) g, (1.34±0.76) g of the control group (P<0.05). There wasno significant difference in the levels of Scr between the two groups before treatment (P>0.05). The Scr levels in the twogroups were significantly lower than those before treatment. One month, 2 months, and 3 months after treatment, the Scrlevels in the combined treatment group were (131.90±12.69) mmol/L, (114.73±8.59) mmol/L, and (105.65±5.51) mmol/L,which were significantly lower than (146.59±13.74) mmol/L, (135.66±12.88) mmol/L, (128.34±10.79) mmol/L in thecontrol group (P<0.05). Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can ef-fectively reduce 24-hour urine protein quantitation and Scr levels, and improve the treatment effect of patients.
【Key words】 Atorvastatin; Benazepril; IgA nephropathy; Efficacy; Urine protein; Serum creatinine
下载PDF